Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML

Eunice S. Wang, MD, chief, Department of Medicine - Leukemia, leader, Leukemia Clinical Disease Team, Roswell Park Comprehensive Cancer Center, discusses the efficacy of adding ziftomenib to intensive induction in the treatment of patients with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia. These findings from the phase 1a KOMET-007 study (NCT05735184) were shared in a presentation at the 2024 ASH Annual Meeting.